Healthcare provider profile · identity verified

Roy A Malphurs, PA

Physician Assistant · MESQUITE, TX · NPI 1699785592

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	344	154
Amlodipine Besylate	Amlodipine Besylate	215	88
Lisinopril	Lisinopril	210	85
Gabapentin	Gabapentin	197	82
Metformin Hcl	Metformin Hcl	178	69
Prednisone	Prednisone	177	112
Tamsulosin Hcl	Tamsulosin Hcl	142	54
Levothyroxine Sodium	Levothyroxine Sodium	135	47
Alendronate Sodium	Alendronate Sodium	110	44
Furosemide	Furosemide	108	47
Albuterol Sulfate Hfa	Albuterol Sulfate	106	39
Simvastatin	Simvastatin	105	39
Rosuvastatin Calcium	Rosuvastatin Calcium	104	44
Eliquis	Apixaban	100	22
Azelastine Hcl	Azelastine Hcl	93	65
Losartan Potassium	Losartan Potassium	90	40
Pantoprazole Sodium	Pantoprazole Sodium	89	33
Metoprolol Succinate	Metoprolol Succinate	88	35
Hydrochlorothiazide	Hydrochlorothiazide	81	27
Fluticasone Propionate	Fluticasone Propionate	77	44
Azithromycin	Azithromycin	76	69
Famotidine	Famotidine	74	26
Montelukast Sodium	Montelukast Sodium	72	32
Omeprazole	Omeprazole	71	40
Trazodone Hcl	Trazodone Hcl	70	27
Acetaminophen-Codeine	Acetaminophen With Codeine	63	15
Tramadol Hcl	Tramadol Hcl	59	16
Meloxicam	Meloxicam	58	25
Escitalopram Oxalate	Escitalopram Oxalate	57	21
Carvedilol	Carvedilol	56	30
Cephalexin	Cephalexin	53	45
Duloxetine Hcl	Duloxetine Hcl	53	12
Zolpidem Tartrate	Zolpidem Tartrate	51	suppressed
Baclofen	Baclofen	50	29
Hydralazine Hcl	Hydralazine Hcl	50	26
Ipratropium Bromide	Ipratropium Bromide	50	20
Clopidogrel	Clopidogrel Bisulfate	47	16
Cefdinir	Cefdinir	44	37
Glipizide	Glipizide	44	15
Glimepiride	Glimepiride	42	18
Metoprolol Tartrate	Metoprolol Tartrate	42	20
Ozempic	Semaglutide	42	suppressed
Atenolol	Atenolol	41	13
Finasteride	Finasteride	41	18
Januvia	Sitagliptin Phosphate	41	14
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	40	15
Alprazolam	Alprazolam	38	suppressed
Farxiga	Dapagliflozin Propanediol	38	suppressed
Allopurinol	Allopurinol	36	14
Citalopram Hbr	Citalopram Hydrobromide	36	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	35	22
Esomeprazole Magnesium	Esomeprazole Magnesium	34	11
Meclizine Hcl	Meclizine Hcl	33	23
Jardiance	Empagliflozin	32	13
Celecoxib	Celecoxib	31	13
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	31	suppressed
Potassium Chloride	Potassium Chloride	31	16
Pravastatin Sodium	Pravastatin Sodium	31	11
Buspirone Hcl	Buspirone Hcl	30	14
Metoclopramide Hcl	Metoclopramide Hcl	29	16
Mupirocin	Mupirocin	28	20
Spironolactone	Spironolactone	26	suppressed
Lorazepam	Lorazepam	25	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	25	suppressed
Pregabalin	Pregabalin	24	11
Ropinirole Hcl	Ropinirole Hcl	24	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	24	suppressed
Diclofenac Sodium	Diclofenac Sodium	23	suppressed
Ibuprofen	Ibuprofen	23	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	22	11
Sertraline Hcl	Sertraline Hcl	21	suppressed
Sucralfate	Sucralfate	21	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	20	suppressed
Mounjaro	Tirzepatide	20	suppressed
Trulicity	Dulaglutide	20	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	19	suppressed
Metformin Hcl Er	Metformin Hcl	19	suppressed
Ondansetron Hcl	Ondansetron Hcl	19	15
Hydroxyzine Hcl	Hydroxyzine Hcl	18	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	18	suppressed
Primidone	Primidone	18	suppressed
Symbicort	Budesonide/Formoterol Fumarate	18	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	17	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	17	11
Nitroglycerin	Nitroglycerin	17	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	16	16
Donepezil Hcl	Donepezil Hcl	16	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	16	suppressed
Methocarbamol	Methocarbamol	16	suppressed
Nifedipine Er	Nifedipine	16	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	16	suppressed
Breo Ellipta	Fluticasone/Vilanterol	15	suppressed
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	15	suppressed
Fluconazole	Fluconazole	15	12
Olmesartan Medoxomil	Olmesartan Medoxomil	15	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	14	suppressed
Benztropine Mesylate	Benztropine Mesylate	14	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	14	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	14	suppressed
Prazosin Hcl	Prazosin Hcl	14	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	14	suppressed
Tizanidine Hcl	Tizanidine Hcl	14	suppressed
Clonazepam	Clonazepam	13	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	13	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	13	12
Levofloxacin	Levofloxacin	13	12
Memantine Hcl	Memantine Hcl	13	suppressed
Carisoprodol	Carisoprodol	12	suppressed
Fenofibrate	Fenofibrate	12	suppressed
Glipizide Er	Glipizide	12	suppressed
Lovastatin	Lovastatin	12	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	12	suppressed
Isosorbide Dinitrate	Isosorbide Dinitrate	11	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	11	suppressed
Torsemide	Torsemide	11	suppressed
Valsartan	Valsartan	11	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	11	suppressed
Ventolin Hfa	Albuterol Sulfate	11	suppressed
Zonisamide	Zonisamide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error